Pharmaceutical giant GlaxoSmithKline this morning pleaded guilty in U.S. District Court in Boston to two counts of introducing misbranded drugs — Paxil and Wellbutrin — into interstate commerce and one count of failing to report safety data about the drug Avandia to the Food and Drug Administration.